Surgery Partners (SGRY) Faces Sales And Debt Questions, Is The Stock Still Undervalued?
Recent commentary around Surgery Partners (SGRY) has focused on weakening unit sales, expectations for softer revenue ahead, and a relatively high net-debt-to-EBITDA position that could limit future financing options.
At a share price of US$14.61, Surgery Partners has seen short-term momentum pick up, with a 7 day share price return of 5.18% and a 30 day share price gain of 4.88%. However, the 1 year total shareholder return is down 29.04%, signalling pressure on longer term holders despite the recent bounce.
Balance the Surgery Partners story by scanning a curated 32 resilient stocks with low risk scores that may offer steadier balance sheets and less financing strain than a highly leveraged provider of surgical facilities.
Surgery Partners now trades at a clear discount to both analyst targets and intrinsic value estimates after that short bounce. The key issue is whether the recent move already reflects fair value or if the gap still matters.
Most Popular Narrative: 18.6% Undervalued
On the most followed view, Surgery Partners is worth about $17.95 per share, which sits above the recent $14.61 close and presents the current discount as a valuation gap rather than a rounding error.
The accelerated migration of high-acuity surgical procedures (particularly orthopedics and joint replacements) from hospitals to outpatient settings is strengthening, with Surgery Partners demonstrating outperformance through investments in robotics and facility capabilities, positioning the company to capture expanding case volumes and higher-revenue procedures that directly support long-term revenue and EBITDA growth.
See why 5 investors see Surgery Partners as 19% undervalued.
Result: Fair Value of $17.95 (UNDERVALUED)
Still, the bullish Surgery Partners narrative could unravel if anesthesia cost pressures persist or if slower acquisition activity keeps EBITDA progress behind analyst expectations.
Find out about the key risks to this Surgery Partners narrative.
Next Steps
Mixed messages on Surgery Partners so far. If you want a clearer picture, move quickly and test the bullish and cautious angles against the underlying numbers, starting with 3 key rewards.
Looking for more investment ideas beyond Surgery Partners?
If Surgery Partners has sharpened your focus on risk and reward, do not stop here. Broader opportunities often sit just outside the first stock on your screen.
- Target resilient balance sheets and fewer surprises by scanning a list of solid balance sheet and fundamentals (25 results) before the next bout of volatility catches you off guard.
- Hunt for mispriced potential and use the 20 high quality undiscovered gems to spot quality businesses the wider market may not be watching yet.
- Protect your downside first and filter for stability through the 32 resilient stocks with low risk scores so you are not relying on hope when conditions change.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com